CompuMed regains OsteoGram rights
Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit
Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit Merck subsidiary that had licensed the technology in 1995 (SCAN 9/13/95). Manhattan Beach, CA-based CompuMed reported that the OsteoGram Analysis Center generated a disappointingly small stream of royalty income.
BMI will return the rights to the OsteoGram technology at no cost to CompuMed, and will discontinue operating the OsteoGram Analysis Center on February 28, according to CompuMed. The company is considering distribution options such as new licensing revenues, as well as worldwide marketing of OsteoGram.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.
